# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-055653
Filing Date
2024-05-08
Accepted
2024-05-08 16:10:55
Documents
72
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | dvax-20240331.htm iXBRL | 10-Q | 2146776
2 | EX-10.1 | dvax-ex10_1.htm | EX-10.1 | 182790
3 | EX-31.1 | dvax-ex31_1.htm | EX-31.1 | 14098
4 | EX-31.2 | dvax-ex31_2.htm | EX-31.2 | 13818
5 | EX-32.1 | dvax-ex32_1.htm | EX-32.1 | 8645
| Complete submission text file | 0000950170-24-055653.txt |  | 9810888

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | dvax-20240331.xsd | EX-101.SCH | 1680523
76 | EXTRACTED XBRL INSTANCE DOCUMENT | dvax-20240331_htm.xml | XML | 1671523

Mailing Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34207 | Film No.: 24926125
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)